Literature DB >> 25112687

Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening.

Sayalee R Chavan1, Radha Charan Dash, M Sarwar Alam, Raj R Hirwani.   

Abstract

Aurora kinases belong to family of highly conserved serine/threonine protein kinases that are involved in diverse cell cycle events and play a major role in regulation of cell division. Abnormal expression of Aurora kinases may lead to cancer; hence, these are considered as a potential target in cancer treatment. In this research article, we identified three novel Aurora A inhibitors using modern computational tools. A four-point common 3D pharmacophore hypothesis of Aurora A (AurA) inhibitors was developed using a diverse set of 55 thienopyrimidine derivatives. A three-dimensional quantitative structure-activity relationship (3D-QSAR) study was carried out using atom-based alignment of diverse set of 55 molecules to evaluate the structure- activity relationships. Docking and 3D-QSAR studies were performed with the 3D structure of AurA to evaluate the generated pharmacophore. The pharmacophore model and 3D-QSAR results complemented the results of our docking study. The pharmacophore hypothesis, which yields the best results, was used to screen the Zinc 'clean drug-like' database. Various database filters such as 3D-arrangement of pharmacophoric features, predicted activity and binding interaction score were used to retrieve hits having potential AurA inhibition activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25112687     DOI: 10.1007/s11030-014-9535-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  19 in total

1.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

Review 2.  Discovery and development of aurora kinase inhibitors as anticancer agents.

Authors:  John R Pollard; Michael Mortimore
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

3.  Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.

Authors:  William J McClellan; Yujia Dai; Cele Abad-Zapatero; Daniel H Albert; Jennifer J Bouska; Keith B Glaser; Terry J Magoc; Patrick A Marcotte; Donald J Osterling; Kent D Stewart; Steven K Davidsen; Michael R Michaelides
Journal:  Bioorg Med Chem Lett       Date:  2011-06-29       Impact factor: 2.823

4.  Pharmacophores in Drug Research.

Authors:  Thierry Langer
Journal:  Mol Inform       Date:  2010-06-28       Impact factor: 3.353

5.  PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.

Authors:  Jitesh P Jani; Joel Arcari; Vincent Bernardo; Samit K Bhattacharya; David Briere; Bruce D Cohen; Kevin Coleman; James G Christensen; Erling O Emerson; Amy Jakowski; Kenneth Hook; Gerrit Los; James D Moyer; Ingrid Pruimboom-Brees; Leslie Pustilnik; Ann Marie Rossi; Stefan J Steyn; Chunyan Su; Konstantinos Tsaparikos; Donn Wishka; Kwansik Yoon; John L Jakubczak
Journal:  Mol Cancer Ther       Date:  2010-03-30       Impact factor: 6.261

Review 6.  Taxanes, microtubules and chemoresistant breast cancer.

Authors:  Barbara T McGrogan; Breege Gilmartin; Desmond N Carney; Amanda McCann
Journal:  Biochim Biophys Acta       Date:  2007-11-12

7.  7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.

Authors:  Terry V Hughes; Stuart L Emanuel; Harold R O'Grady; Peter J Connolly; Catherine Rugg; Angel R Fuentes-Pesquera; Prabha Karnachi; Richard Alexander; Steven A Middleton
Journal:  Bioorg Med Chem Lett       Date:  2008-07-26       Impact factor: 2.823

8.  HEF1-dependent Aurora A activation induces disassembly of the primary cilium.

Authors:  Elena N Pugacheva; Sandra A Jablonski; Tiffiney R Hartman; Elizabeth P Henske; Erica A Golemis
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

9.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Authors:  Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-26       Impact factor: 11.205

10.  Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Authors:  G M T Cheetham; P A Charlton; J M C Golec; J R Pollard
Journal:  Cancer Lett       Date:  2007-01-19       Impact factor: 8.679

View more
  1 in total

1.  Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model.

Authors:  Natalya I Vasilevich; Victor V Tatarskiy; Elena A Aksenova; Denis N Kazyulkin; Ilya I Afanasyev
Journal:  Pharmaceuticals (Basel)       Date:  2016-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.